Literature DB >> 28695755

Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.

Moussab Damlaj1,2,3, Mohammed Al Balwi2,3,4, Areej M Al Mugairi4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28695755     DOI： 10.1080/10428194.2017.1347653

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  B-cell Prolymphocytic Leukemia: Case Report and Challenges on a Diagnostic and Therapeutic Forefront.

Authors:  Bikramjit S Bindra; Harpreet Kaur; Shellsea Portillo; Oluwadunni Emiloju; Katherine Garcia de de Jesus
Journal:  Cureus       Date:  2019-09-11

Review 2.  Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.

Authors:  Lijie Xing; Qiang He; Linna Xie; Hui Wang; Zengjun Li
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 9.941
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.